European Regulators Recommend Approval of Zealand Pharma’s Zeydovio for Short Bowel Syndrome

Danish biotechnology firm Zealand Pharma has secured a crucial regulatory milestone in Europe, after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of its specialty therapeutic, Zeydovio, for the treatment of short bowel syndrome. The positive opinion issued by the committee marks a significant step forward for the company’s clinical pipeline, shifting its focus from metabolic and obesity research toward complex, rare gastrointestinal disorders.

Short bowel syndrome is a severe, often life-threatening condition that occurs when a large portion of the small intestine is surgically removed, typically due to Crohn's disease, trauma, or vascular accidents. Patients with the condition are frequently unable to absorb sufficient nutrients and water from food, leading to chronic malnutrition, dehydration, and a heavy reliance on parenteral support—intravenous administration of nutrition and fluids. The introduction of targeted pharmacological treatments aims to enhance intestinal adaptation, potentially reducing patients' dependence on intravenous feeding and improving their overall quality of life.

The CHMP's recommendation is based on comprehensive clinical trial data evaluating the efficacy and safety profile of Zeydovio in managing the debilitating symptoms associated with the syndrome. While the EMA committee's green light is not a final commercial authorization, the European Commission typically adopts the CHMP's scientific recommendations within a couple of months, effectively paving the way for the drug's marketing authorization across member states. For Zealand Pharma, this upcoming approval represents a pivotal diversification of its commercial portfolio, moving beyond its well-known partnerships and pipeline entries in the burgeoning obesity and diabetes sectors.

As regulatory processes advance toward final European approval, the decision underscores the growing industry focus on specialized therapeutics addressing unmet medical needs in rare diseases. The commercialization of Zeydovio will position Zealand Pharma to establish a direct footprint in the European specialty care market, providing healthcare providers with a newly validated option for managing patients with compromised intestinal function.